ArticleRSC advances2025
Pyrido-indole-one hybrids as potential anticancer agents against breast carcinoma: development of Ru(ii)-catalyzed annulation of indole-2-carboxamides, biological screening and molecular docking studies.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacological inhibition of CDK7 and CDK9 suppresses gastrointestinal (colon) cancer progression through modulation of stemness, epithelial-mesenchymal transition, and chemoresistance.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer continues to pose a major worldwide health concern, characterized by its complexity and the diverse nature of its molecular subtypes. Among these, triple-negative breast cancers (TNBCs) present a formidable obstacle due to their aggressive progression and lack of targeted hormonal therapies. Molecular hybridization is a compelling strategy in drug design and development, combining distinct bioactive components to enhance potency and selectivity. Herein, we present the design and synthesis of a new series of pyrido-indole-one hybrids featuring a β-carboline core, by utilizing the molecular hybridization strategy, integrating indole-2-carboxamides with ynone functionalities to mitigate TNBC progression. A novel synthetic approach has been devised for synthesizing hybrid molecules, employing annulation of indole-2-carboxamides with ynones, facilitated by a Ru-complex catalyst. All the reaction conditions are meticulously optimized to yield the target hybrid molecules. Among the synthesized hybrids, 9c exhibits strong anticancer potency against MCF-7, 4T1 and MDA-MB-231 breast carcinoma cell lines with IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.